|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NOP10 |
Gene summary for NOP10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NOP10 | Gene ID | 55505 |
| Gene name | NOP10 ribonucleoprotein | |
| Gene Alias | DKCB1 | |
| Cytomap | 15q14 | |
| Gene Type | protein-coding | GO ID | GO:0000154 | UniProtAcc | Q9NPE3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55505 | NOP10 | LZE21T | Human | Esophagus | ESCC | 1.53e-03 | 8.85e-01 | 0.0655 |
| 55505 | NOP10 | LZE6T | Human | Esophagus | ESCC | 3.79e-10 | 9.89e-01 | 0.0845 |
| 55505 | NOP10 | P1T-E | Human | Esophagus | ESCC | 2.28e-15 | 1.54e+00 | 0.0875 |
| 55505 | NOP10 | P2T-E | Human | Esophagus | ESCC | 2.29e-15 | 3.74e-01 | 0.1177 |
| 55505 | NOP10 | P4T-E | Human | Esophagus | ESCC | 2.27e-63 | 2.03e+00 | 0.1323 |
| 55505 | NOP10 | P5T-E | Human | Esophagus | ESCC | 1.11e-49 | 1.36e+00 | 0.1327 |
| 55505 | NOP10 | P8T-E | Human | Esophagus | ESCC | 7.36e-61 | 1.67e+00 | 0.0889 |
| 55505 | NOP10 | P9T-E | Human | Esophagus | ESCC | 2.87e-54 | 1.76e+00 | 0.1131 |
| 55505 | NOP10 | P10T-E | Human | Esophagus | ESCC | 1.34e-47 | 1.13e+00 | 0.116 |
| 55505 | NOP10 | P11T-E | Human | Esophagus | ESCC | 3.12e-22 | 1.53e+00 | 0.1426 |
| 55505 | NOP10 | P12T-E | Human | Esophagus | ESCC | 5.81e-65 | 1.54e+00 | 0.1122 |
| 55505 | NOP10 | P15T-E | Human | Esophagus | ESCC | 2.32e-35 | 1.11e+00 | 0.1149 |
| 55505 | NOP10 | P16T-E | Human | Esophagus | ESCC | 9.97e-15 | 5.26e-01 | 0.1153 |
| 55505 | NOP10 | P17T-E | Human | Esophagus | ESCC | 1.07e-11 | 9.73e-01 | 0.1278 |
| 55505 | NOP10 | P19T-E | Human | Esophagus | ESCC | 2.85e-15 | 1.90e+00 | 0.1662 |
| 55505 | NOP10 | P20T-E | Human | Esophagus | ESCC | 2.73e-41 | 1.18e+00 | 0.1124 |
| 55505 | NOP10 | P21T-E | Human | Esophagus | ESCC | 1.33e-78 | 1.89e+00 | 0.1617 |
| 55505 | NOP10 | P22T-E | Human | Esophagus | ESCC | 1.18e-57 | 1.38e+00 | 0.1236 |
| 55505 | NOP10 | P23T-E | Human | Esophagus | ESCC | 4.68e-54 | 1.75e+00 | 0.108 |
| 55505 | NOP10 | P24T-E | Human | Esophagus | ESCC | 4.85e-28 | 1.04e+00 | 0.1287 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002261310 | Cervix | CC | ribonucleoprotein complex biogenesis | 88/2311 | 463/18723 | 2.11e-05 | 3.82e-04 | 88 |
| GO:004225410 | Cervix | CC | ribosome biogenesis | 62/2311 | 299/18723 | 2.48e-05 | 4.27e-04 | 62 |
| GO:000640310 | Cervix | CC | RNA localization | 43/2311 | 201/18723 | 2.00e-04 | 2.29e-03 | 43 |
| GO:00160727 | Cervix | CC | rRNA metabolic process | 42/2311 | 236/18723 | 9.12e-03 | 4.60e-02 | 42 |
| GO:00007239 | Cervix | CC | telomere maintenance | 26/2311 | 131/18723 | 9.33e-03 | 4.66e-02 | 26 |
| GO:002261315 | Cervix | HSIL_HPV | ribonucleoprotein complex biogenesis | 52/737 | 463/18723 | 9.85e-12 | 6.81e-09 | 52 |
| GO:004225415 | Cervix | HSIL_HPV | ribosome biogenesis | 40/737 | 299/18723 | 1.25e-11 | 6.81e-09 | 40 |
| GO:00063647 | Cervix | HSIL_HPV | rRNA processing | 27/737 | 225/18723 | 2.67e-07 | 1.55e-05 | 27 |
| GO:001607215 | Cervix | HSIL_HPV | rRNA metabolic process | 27/737 | 236/18723 | 6.96e-07 | 3.57e-05 | 27 |
| GO:00344706 | Cervix | HSIL_HPV | ncRNA processing | 27/737 | 395/18723 | 4.01e-03 | 3.45e-02 | 27 |
| GO:0022613 | Colorectum | AD | ribonucleoprotein complex biogenesis | 151/3918 | 463/18723 | 1.96e-09 | 1.39e-07 | 151 |
| GO:0006403 | Colorectum | AD | RNA localization | 71/3918 | 201/18723 | 1.54e-06 | 4.76e-05 | 71 |
| GO:0000723 | Colorectum | AD | telomere maintenance | 43/3918 | 131/18723 | 9.77e-04 | 9.20e-03 | 43 |
| GO:0010833 | Colorectum | AD | telomere maintenance via telomere lengthening | 29/3918 | 81/18723 | 1.42e-03 | 1.22e-02 | 29 |
| GO:0071897 | Colorectum | AD | DNA biosynthetic process | 55/3918 | 180/18723 | 1.46e-03 | 1.24e-02 | 55 |
| GO:0042254 | Colorectum | AD | ribosome biogenesis | 84/3918 | 299/18723 | 1.82e-03 | 1.50e-02 | 84 |
| GO:0007004 | Colorectum | AD | telomere maintenance via telomerase | 25/3918 | 69/18723 | 2.43e-03 | 1.88e-02 | 25 |
| GO:0006278 | Colorectum | AD | RNA-dependent DNA biosynthetic process | 25/3918 | 75/18723 | 8.36e-03 | 4.89e-02 | 25 |
| GO:00226131 | Colorectum | SER | ribonucleoprotein complex biogenesis | 112/2897 | 463/18723 | 5.01e-07 | 2.48e-05 | 112 |
| GO:00064031 | Colorectum | SER | RNA localization | 53/2897 | 201/18723 | 4.51e-05 | 1.13e-03 | 53 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NOP10 | SNV | Missense_Mutation | c.24N>G | p.Asn8Lys | p.N8K | Q9NPE3 | protein_coding | tolerated(0.08) | benign(0.158) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| NOP10 | SNV | Missense_Mutation | c.157A>G | p.Lys53Glu | p.K53E | Q9NPE3 | protein_coding | deleterious(0.01) | benign(0.067) | TCGA-DD-AACY-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| NOP10 | SNV | Missense_Mutation | novel | c.12N>T | p.Gln4His | p.Q4H | Q9NPE3 | protein_coding | deleterious(0.04) | benign(0.001) | TCGA-DD-AAW3-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| NOP10 | SNV | Missense_Mutation | novel | c.173A>T | p.Gln58Leu | p.Q58L | Q9NPE3 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-MN-A4N4-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NOP10 | SNV | Missense_Mutation | c.152N>C | p.Arg51Pro | p.R51P | Q9NPE3 | protein_coding | deleterious(0.02) | possibly_damaging(0.726) | TCGA-34-5232-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |